ライフサイエンスコーパス: bone scan

1 hanges in PSA will often antedate changes in bone scan.

2 y on the leukocyte study, as compared to the bone scan.

3 ent a dual-energy X-ray absorptiometry (DXA) bone scan.

4 ocyte studies were also interpreted with the bone scans.

5 itation of metastases from planar whole-body bone scans.

6 s, lymphangiograms, staging laparatomies and bone scans.

7 (PSA), measurable disease, and radionuclide bone scans.

8 99m)Tc-methylene diphosphonate ((99m)Tc-MDP) bone scans.

9 n bone metastases as detected by (99m)Tc-MDP bone scans.

10 bone marrow scanning and 99mTc-diphosphonate bone scanning.

11 surveys; five infants also underwent nuclear bone scanning.

12 Conventional (99m)Tc-methylene diphosphonate bone scans, (201)Tl tumor imaging, and PET techniques ha

13 e rates with (131)I-MIBG scan (64%; P = .1), bone scan (36%; P < .001), and BM histology (34%; P < .0

14 %), and/or appearance of new bone lesions on bone scan (83%).

15 ysis, paired (99m)Tc-methylene diphosphonate bone scans ((99m)Tc-BS) were available for 35 patients a

16 Compared with the standard-of-care bone scanning, (99m)Tc-MIP-1404 and (99m)Tc-MIP-1405 ide

17 hildren: (99m)Tc-methylene diphosphate (MDP) bone scans, (99m)Tc-mercaptoacetyltriglycine (MAG3) reno

18 The purpose of this study was to reveal the bone scan abnormalities in children with leukemia and to

19 e evaluated for the presence of asymptomatic bone scan abnormalities in the lower extremities.

20 mprised 747 men with rising PSA and negative bone scan after surgery (n = 486) or radiation therapy (

21 Within 3 months of diagnosis, 43% had a bone scan and 20% a computed tomography (CT) scan.

22 it possible to perform a dynamic total-body bone scan and a dynamic hepatobiliary scan with time res

23 The remaining two modalities (bone scan and computed tomography [CT]) were used so inf

24 Bone scan and computed tomography scan of the pelvis sho

25 omography scans of the chest and abdomen and bone scan and have a patent main portal vein and major h

26 steoarthritis are mostly unknown, lesions on bone scan and mechanical malalignment increase risk for

27 Twenty-eight patients who received both bone scan and plasma fluoride measurements for skeletal

28 Radionuclide bone scanning and CT supplement clinical and biochemical

29 ly replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the t

30 In 32 patients, bone scanning and PSMA PET were performed before therapy

31 In 31 patients, bone scanning and radiologic imaging were performed for

32 Bone scans and anthropometric and dietary assessments we

33 Bone scans and brain imaging were not obtained in 34% an

34 f beneficiaries with breast cancer underwent bone scans and half of beneficiaries with lung cancer or

35 Early and delayed whole-body bone scans and radiographs were reviewed retrospectively

36 ce imaging [MRI], selective angiography, and bone scanning) and somatostatin receptor scintigraphy do

37 rcent to 76% of women had a mammogram, 24% a bone scan, and 14% a CT scan in the 0-18 and 18-36 month

38 Radiographic, bone scan, and CT severity were not related to time to h

39 e lesions, improvement in PFS, resolution of bone scans, and reductions in bone turnover markers, pai

40 Bone marrow aspirate and biopsy and bone scan are unnecessary in at least one third of patie

41 Bone scans are reported as "new lesions" or "no new lesi

42 There were 25 subjects who underwent bone scans at both time points (baseline and week 12) an

43 Similarly, patients with positive bone scans at diagnosis had worse EFS than those with ne

44 sive disease, and five did not have a repeat bone scan because of PSA progression.

45 r MRI, and a (99m)Tc-methylene diphosphonate bone scan) before enrollment.

46 Two ADPCa patients had positive bone scans; both improved.

47 Physicians often order periodic bone scans (BS) to check for metastases in patients with

48 For women with only an abnormal bone scan but without bony destruction by imaging studie

49 MIBG scans showed more skeletal lesions than bone scans, but the normally high physiologic brain upta

50 However, the accuracy of bone scanning can be improved with the addition of SPECT

51 uted tomography, magnetic resonance imaging, bone scanning, cardiovascular nuclear imaging, nonobstet

52 improved understanding of treatment-induced bone scan changes.

53 nt metastases were diagnosed by radionuclide bone scan, chest radiograph, or other body imaging, whic

54 of a conventional staging approach including bone scanning, chest radiography, or dedicated CT and ab

55 Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts,

56 The use of CBCs, chemistry panels, bone scans, chest radiographs, liver ultrasounds, comput

57 of complete blood counts, chemistry panels, bone scans, chest radiographs, liver ultrasounds, pelvic

58 ine-131 metaiodobenzylguanidine (MIBG) scan, bone scan, computed tomography (and/or magnetic resonanc

59 Diagnostic applications such as the bone scan continue to be the most common use in oncology

60 imaging studies-including chest radiography; bone scanning; contrast material-enhanced computed tomog

61 to 5 subgroups, each containing 10 simulated bone scans, corresponding to BSI values of 0.5, 1.0, 3.0

62 retation of the PET images was compared with bone scan, CT, and clinical follow-up findings.

63 A subsequent bone scan demonstrated evolution of the vascular comprom

64 The bone scan did not reveal evidence of osteomyelitis.

65 Scan Index, is based on an inspection of the bone scan, estimating visually the fraction of each bone

66 /pelvis scans, three limited MRI scans, four bone scans, five gallium scans, two laparotomies and one

67 d the following features at the time of each bone scan for association with a positive BS: preoperati

68 ntrast material enhancement and radionuclide bone scanning for detection of brain or skeletal metasta

69 MR imaging was no more accurate than bone scanning for skeletal evaluation.

70 A bone scan from an outside hospital was reviewed, and fur

71 The mouse bone scan had improved image resolution using the PET in

72 Bone scan had significantly lower specificity and sensit

73 Although planar bone scanning has recognized limitations, in particular,

74 Traditional skeletal survey and bone scans have sensitivity limitations for osteolytic l

75 Good correlation was seen with bone scanning; however, more lesions were demonstrated w

76 etraacetic acid ((51)Cr-EDTA) and whole-body bone scan images were acquired at 10 min, 1, 2, 3, and 4

77 We examined baseline and 12-wk bone scan images.

78 When interpreted with bone scans, images obtained in the antibody and (111)In-

79 we describe the importance of the whole-body bone scan in diagnosing the multifocality of chronic rec

80 correctly positive in seven, SRS in six, and bone scan in five.

81 nning may enhance the diagnostic accuracy of bone scanning in the evaluation of children with skeleta

82 to gain insight about the effects of TKIs on bone scans in prostate cancer, we systematically evaluat

83 on MR images in four of five patients and on bone scans in three of five patients.

84 d 153Sm indicate a reduction of hot spots on bone scans in up to 70% of patients, and suggest a possi

85 Guidelines for the use of bone scanning (in patients with PSA level > 10 ng/mL) an

86 68% of evaluable patients had improvement on bone scan, including complete resolution in 12%.

87 ffusion volume (tDV) was correlated with the bone scan index (BSI) and other prognostic factors by us

88 to evaluate the performance of the automated bone scan index (BSI) as an imaging biomarker in patient

89 The bone scan index (BSI) is a promising candidate, being a

90 e prostate-specific antigen blood value, the bone scan index (BSI), and disease classification using

91 skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who have advanced met

92 quantify metastatic bone lesions, called the Bone Scan Index, is based on an inspection of the bone s

93 asurement of fluoride may be considered when bone scan is not readily available.

94 Use of alendronate before bone scanning is unlikely to result in decreased detecti

95 ourse, including surgical interventions, and bone scans is described.

96 Skeletal scintigraphy (bone scan) is very sensitive in the detection of osseous

97 an response, defined as >/= 30% reduction in bone scan lesion area.

98 on magnetic resonance imaging correspond to bone scan lesions.

99 While use of radiographs and bone scan may be important to rule out other entities, M

100 Single- or multiphasic bone scans may localize common soft-tissue tumors in neu

101 efining disease status requires CT (or MRI), bone scan, metaiodobenzylguanidine (MIBG) scan, bone mar

102 Nuclear imaging techniques such as bone scans, metaiodobenzylguanidine (MIBG) scans, and (1

103 is of leukemia was suggested on the basis of bone scans obtained as part of the initial work-up for u

104 he medical records and two-phase, whole-body bone scans of 14 patients (mean age 10.5 yr) with the di

105 y-phase knee scans and late-phase whole-body bone scans of 15 additional joint sites were scored semi

106 hanges (kappa = 0.70, P < 0.0001) was in the bone scans of 173 patients.

107 The mean BSI difference between the 2 repeat bone scans of 35 patients was 0.05 (SD = 0.15), with an

108 Follow-up bone scan study: 2 follow-up bone scans of metastatic prostate cancer patients were a

109 of standardizing quantitative changes in the bone scans of patients with metastatic prostate cancer.

110 to standardize the evaluation of changes in bone scans of prostate cancer patients with skeletal met

111 hus highlight the importance of performing a bone scan or PET CT in cases of carcinoma of the gall bl

112 aphy (CT), magnetic resonance imaging (MRI), bone scan, or other imaging modalities.

113 Cabozantinib resulted in improvements in bone scans, pain, analgesic use, measurable soft tissue

114 Within that group of 25, we found 5 bone scan partial responses and 1 complete response.

115 defined as >/= two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory

116 Group A patients with bone scans positive for facet joint abnormalities receiv

117 )In-labeled leukocyte study, the three-phase bone scanning procedure, and dual-tracer studies.

118 PET is used as the gatekeeper in addition to bone scanning, radionuclide therapy with (223)Ra may be

119 PET is used as the gatekeeper in addition to bone scanning, radionuclide therapy with (223)Ra may be

120 competitive interference with 99mTc-labeled bone scanning reagents.

121 Bone scan response (BSR) at week 12 as assessed by indep

122 hese outcomes were observed in both cohorts: bone scan response in 73% and 45%, respectively; reducti

123 found a relatively high rate of (99m)Tc-MDP bone scan response to sunitinib among men with metastati

124 The primary end point was bone scan response, defined as >/= 30% reduction in bone

125 Ninety-one patients (63%) had a bone scan response, often by week 6.

126 to define the incidence of at least partial bone scan response.

127 e found that none of the subjects exhibiting bone scan responses experienced concordant improvements

128 A nomogram for predicting the bone scan result was constructed with an overfit-correct

129 ine physician, who had full knowledge of the bone scan results.

130 the correlation between plasma fluoride and bone scan results.

131 ated most strongly with the early-phase knee bone scan scores (P = 0.0003), even after adjustment for

132 for OA severity according to the late-phase bone scan scores (P = 0.015), as well as synovial fluid

133 m COMP levels correlated with the total-body bone scan scores (r = 0.188, P = 0.018) and with a facto

134 There was no correlation between bone scan scores and outcome following induction therapy

135 P = 0.018) and with a factor composed of the bone scan scores in the shoulders, spine, lateral knees,

136 modeling was used in the correlation of the bone scan scores with the COMP levels.

137 A bone scan showed diffuse bony involvement including the

138 Simulation study: bone scan simulations with predefined tumor burdens were

139 Follow-up bone scan study: 2 follow-up bone scans of metastatic pr

140 Repeat bone scan study: to assess the reproducibility in a rout

141 regression, and improvement on radionuclide bone scans than did patients with androgen-independent p

142 and protein C deficiency was referred for a bone scan to rule out osteomyelitis of the right tibia.

143 tivity and specificity, are recommended over bone scanning to screen for bone metastases in patients

144 s, women seeing medical oncologists had more bone scans, tumor antigen testing, chest x-rays, and che

145 We measured bone scans, tumor antigen tests, chest x-rays, and other

146 Of 25 patients with positive bone scans, two had improvement, seven had stable diseas

147 tigraphic response was evaluated by MIBG and bone scans using a semi-quantitative scoring system.

148 The number of lesions detected by bone scan varied from 1-18 (mean 6).

149 diagnosing bone lesions was 89.7% for planar bone scanning versus 98.3% for (18)F-FDG PET/CT.

150 Increased tracer uptake on bone scan was considered positive for periostitis.

151 Bone scan was positive in 52 patients, MRI in seven, and

152 Bone scan was routine through 2002.

153 99mTc-methylene diphosphonate (MDP) bone scanning was performed before they received alendro

154 Quantitative whole-body bone scanning was performed, and radioactivity deposited

155 87 y) attending our department for a routine bone scan were injected with 600 MBq (99m)Tc-MDP, and 4

156 Alkaline phosphatase and technetium bone scan were sensitive ways of detecting early disease

157 osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30

158 results of the monoclonal antibody study and bone scanning were more accurate (0.91) for diagnosing t

159 Bone scans were evaluated for geographic and anatomic lo

160 Bone scans were interpreted as positive for osteomyeliti

161 iphase (99m)Tc-hydroxyethylene diphosphonate bone scans were negative early, but late-phase (>3 h) up

162 efinitive therapy for localized disease, (b) bone scans were negative, and (c) anti-3-(18)F-FACBC pos

163 Bone scans were obtained by pQCT from the distal epiphys

164 lity in a routine clinical setting, 2 repeat bone scans were obtained from metastatic prostate cancer

165 (99m)Tc-hydroxymethylene diphosphonate bone scans were only positive at day 14 in RA versus sha

166 ultiphase 99mTc methylenediphosphonate (MDP) bone scans were performed in five patients with neurofib

167 Baseline radionuclide bone scans were reviewed in 191 assessable patients with

168 Fifty bone scans were simulated with a tumor burden ranging fr

169 , magnetic resonance image, angiography, and bone scan) were performed, and the management was propos

170 egion demonstrating abnormal activity on the bone scan, which was more intense than adjacent marrow a

171 Dynamic bone scanning with (99m)Tc-labeled diphosphonates and (1